drugset
drugset / Trial / NCT01787149

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis

NCT01787149 ↗

Phase 3 Unknown 98 enrolled Mycenax Biotech Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination with DMARDs versus DMARDs Alone in Patients with Rheumatoid Arthritis

Timeline

Start
2013-09
Primary completion
2017-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg —

Indications

No indication recorded.